Primary lymphoma of the uterine cervix: A systematic review and integrated analysis of case reports and series
- Authors:
- Published online on: January 21, 2025 https://doi.org/10.3892/ol.2025.14896
- Article Number: 150
-
Copyright : © Kechagias et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Evidence on the diagnosis and management of women with primary lymphoma of the uterine cervix (PLUC) is limited. The present study performed a systematic review of the literature and provided an overview of the reported cases of PLUC. A total of 213 reports were included, which comprised 339 patients with PLUC. The mean age of the patients was 48.5 years (median, 46 years; age range, 15‑88 years). The most common presenting symptom was vaginal bleeding (189/318, 59.4%) and its duration ranged from 4.5 days to 24 months, with only a small fraction of patients developing ‘B’ symptoms including weight loss, night sweats and fever (28/318, 8.8%). Biopsy (either excisional or punch biopsy) was the most commonly used initial/primary diagnostic modality (78/278, 28.1%) followed by ultrasound (59/278, 21.2%). The most common management approach out of 309 patients was surgery (with or without adjuvant or neo‑adjuvant treatment; 115/309), followed by chemotherapy alone (109/309), which was followed by chemo‑radiotherapy alone (62/309). The follow‑up period for survivors ranged from 4 weeks to 246 months, and the absolute 5‑year and 10‑year survival rates were 86.1 and 85.4%, respectively. The relatively low number of patients and high heterogeneity did not permit a robust comparative analysis of the survival outcomes. However, the longest median survival was reported for women who received neo‑adjuvant chemotherapy followed by surgery (15 patients; 72 months). Although malignant PLUC is rare, early detection, optimal therapeutic management, and multidisciplinary involvement of gynecologic oncologists and lymphoma specialists may offer benefit to patients diagnosed with this rare disease.
